Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation and expansion study of XB010 alone and in combination in advanced solid tumors
NL-OMON61510Phase 1Not yet recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of XB010 in Nonhematologic neoplasms (2 arms), sponsored by Exelixis, Inc. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
XB010
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON61510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61510.